Table 1.

Selected ongoing clinical trials in the treatment of PCa.

No.	Intervention	Selected population	Phase	ClinicalTrials.gov identifier:
1.	Sipuleucel-T with Radium -223 versus Sipuleucel-T alone	Minimally symptomatic or asymptomatic mCRPC	II	NCT02463799
2.	Radiation therapy with Sipuleucel-T versus Sipuleucel-T alone	Hormone resistance metastatic PCa	II	NCT01807065
3.	Combination of radiation and Sipuleucel-T	mCRPC	Observational study	NCT02232230
4.	Sipuleucel-T and stereotactic ablative body radiation	mCRPC	II	NCT01818986
			I	NCT01833208
5.	Sipuleucel-T + oral Indoximod	mCRPC	II	NCT01560923
6.	Sipuleucel T with Ipilimumab	Advanced prostate cancer	I	NCT01832870
7.	Immediate versus delayed co treatment with Sipuleucel T + Ipilimumab	Chemotherapy naïve mCRPC	II	NCT01804465
8.	ProstAtak + valacyclovir with radiation versus placebo + valacyclovir with radiation	Localised PCa	III	NCT01436968
9.	PROSTVAC in Combination with Nivolumab	mCRPC	I/II	NCT02933255
10.	Enzalutamide with ProstVac-V/F versus Enzalutamide alone	Non metastatic castration sensitive pCa	II	NCT01875250
11.	Enzaluatmide with ProstVac-V/F versus Enzalutamide alone	mCRPC	II	NCT01867333
12.	ProstVac-V/F + bi-functional fusion protein MSB0011359C + CV301 vaccine	Biochemically recurrent pCa	II	NCT03315871
13.	Ad5-PSA	Hormone refractory metastatic pCa	II	NCT00583024
14.	Ad5-PSA with ADT (androgen deprivation therapy) versus Ad5-PSA alone	Recurrent pCa after local therapy	II	NCT00583752
15.	Pembrolizumab with pTGV-HP Plasmid DNA Vaccine	Hormone resistance metastatic pCa	I/II	NCT02499835
16.	pTGV-HP vaccine with GM-CSF versus GM-CSF alone	Non metastatic pCa	II	NCT01341652

Ad5, adenovirus type 5; GM-CSF, granulocyte-macrophage colony-stimulating factor; mCRPC, metastatic castration resistant PCa; PCa, prostate cancer; PSA, prostate specific antigen.